HLA-E Antibody (3H2679): sc-71262

HLA-E Antibody (3H2679) is a mouse monoclonal IgG1 kappa light chain antibody that detects HLA-E protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-HLA-E antibody (3H2679) is available as the non-conjugated format. HLA-E plays a crucial role in the immune system by presenting a limited set of peptides derived from the leader sequences of other major histocompatibility complex (MHC) class I molecules, which is essential for the regulation of natural killer (NK) cell activity. This selective peptide presentation is vital for maintaining immune tolerance and preventing inappropriate activation of NK cells, which can lead to autoimmune responses. HLA-E is primarily located on the cell surface, where HLA-E interacts with inhibitory receptors on NK cells, thereby modulating their cytotoxic activity. HLA-E′s ability to bind these peptides and present them to immune cells underscores HLA-E′s importance in immune surveillance and response, making HLA-E a significant marker in studies related to transplantation, cancer immunology, and infectious diseases. The structural composition of HLA-E, as a heterodimer consisting of a heavy chain anchored in the membrane and a light chain, further emphasizes HLA-E′s specialized function in the immune system, distinguishing HLA-E from other MHC class I molecules.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HLA-E Antibody (3H2679) References:

1. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules.  |  Menier, C., et al. 2003. Hum Immunol. 64: 315-26. PMID: 12590976
2. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines.  |  Palmisano, GL., et al. 2005. Hum Immunol. 66: 1-12. PMID: 15620456
3. Lack of association between HLA-E polymorphism and primary cutaneous melanoma in Spanish patients.  |  Moya-Quiles, MR., et al. 2005. J Dermatol Sci. 40: 62-4. PMID: 16153808
4. Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion.  |  Mazzarino, P., et al. 2005. Eur J Immunol. 35: 3240-7. PMID: 16224817
5. Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1.  |  Lajoie, J., et al. 2006. J Infect Dis. 193: 298-301. PMID: 16362895
6. The involvement of HLA-E and -F in pregnancy.  |  Ishitani, A., et al. 2006. J Reprod Immunol. 69: 101-13. PMID: 16487601
7. Comparison of the expression of human leukocyte antigen (HLA)-G and HLA-E in women with normal pregnancy and those with recurrent miscarriage.  |  Bhalla, A., et al. 2006. Reproduction. 131: 583-9. PMID: 16514201
8. The orthology of HLA-E and H2-Qa1 is hidden by their concerted evolution with other MHC class I molecules.  |  Joly, E. and Rouillon, V. 2006. Biol Direct. 1: 2. PMID: 16542007
9. HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma.  |  Yang, Y., et al. 2021. Front Oncol. 11: 670673. PMID: 34178656
10. HLA-E circulating and genetic determinants in schizophrenia and bipolar disorder.  |  Boukouaci, W., et al. 2021. Sci Rep. 11: 20260. PMID: 34642395
11. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors.  |  Mac Donald, A., et al. 2023. Front Immunol. 14: 1231916. PMID: 37675109
12. Viral sequence determines HLA-E-restricted T cell recognition of hepatitis B surface antigen.  |  Murugesan, G., et al. 2024. Nat Commun. 15: 10126. PMID: 39578466

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HLA-E Antibody (3H2679) has 3 citations in a variety of scientific publications.

Primary antibodies like Anti-HLA-E Antibody (3H2679) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HLA-E Antibody (3H2679) Specifications

Alternate Product Name: HLAE

Product Clone Name: 3H2679

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: HLA-E denatured heavy chain

Epitope Species: human

Product Reactivity/Detection: denatured heavy chain of HLA-E

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P)

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 3 citations in various scientific publications

Available Conjugates/Forms for HLA-E Antibody (3H2679): N/A